STIM — Neuronetics, Inc.
Is STIM overbought or oversold? Here is the current MarketMoodz read.
Neuronetics, Inc. (STIM) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $1.25. The rating moved from Neutral to Strong Oversold on November 13, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$1.25
- Last changeMoved from Neutral to Strong Oversold on November 13, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
Neuronetics, Inc. (STIM) is a small‑cap medical‑device company focused on TMS therapy with a commercial footprint that benefits from outpatient behavioral‑health trends and potential reimbursement wins. Revenue and cash‑flow prospects depend heavily on procedure adoption, payer coverage, and the company’s ability to manage financing needs. Recent sector readthroughs that favor outpatient and at‑home behavioral‑health channels are supportive, but limited social/research coverage and small‑cap liquidity constraints raise execution and dilution risks. Near‑term catalysts include expanded coverage, stronger clinic procedure growth, and potential new indications; downside scenarios stem from slower adoption, reimbursement setbacks, competition, or the need to raise capital.
Key factors
- Established presence in TMS (transcranial magnetic stimulation) therapy with an installed base and commercial footprint in behavioral-health clinics and physicians' offices
- Revenue growth tied to procedure volume expansion, clinic adoption, and reimbursement clarity (including potential Medicare Advantage impact)
- Sector theme support for outpatient and at‑home behavioral‑health modalities (readthrough from recent regulatory approvals in at‑home treatments)
- Limited public sentiment and research coverage available, increasing information asymmetry for retail investors
- Small‑cap liquidity and balance‑sheet sensitivity to capital markets and potential dilutive financing decisions
Risks
- Slow commercial adoption or slower-than-expected procedure growth versus expectations
- Adverse changes or delays in reimbursement and coverage policies (Medicare/MA payors uncertainty)
- Competition from alternative therapies (pharmaceuticals, ketamine/ES ketamine clinics, other device makers) and new at‑home technologies
- Liquidity and financing risk for a low‑price/small‑cap issuer, including potential dilution if capital is raised
- Regulatory setbacks or unfavorable clinical-readout risks for expanded indications
- Macro/market risk: low investor appetite for microcaps during risk-off periods which can amplify share price volatility
See today's live rating, score and targets
Members see the live hourly rating for STIM — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.